Lowest Price Guaranteed From USD 4,899
Published
May 2020
Pages
275
View Count
12211
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The viral vector purification market is estimated to be worth $155 million currently and is expected to grow at compounded annual growth rate (CAGR) of 21.0% during the forecast period. Since the approval and launch of cell and gene therapy products, such as Zolgensma® (2019), ZYNTEGLO™ (2019), Luxturna® (2017), KYMRIAH® (2017) and YESCARTA® (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019. Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in this domain. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings. Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.
A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging. Existing separation and purification techniques are not efficient when it comes to purifying viral vectors at large scales. Moreover, these techniques are often unable to separate complete viruses from empty capsids, thereby, compromising product recovery. Therefore, it has become essential for stakeholders to develop innovative ways to optimize the purification process, in order to further improve virus recovery and facilitate effective removal of contaminants / impurities. Currently, the viral vector purification products market is driven by abovementioned surge in demand for viral vectors. In this context, it is worth mentioning that there are several virus based vaccines under development against the novel SARS-CoV-2 coronavirus strain. In fact, according to the WHO, there are over 20 viral vaccines currently being investigated against the novel coronavirus. Developing the means to better purify viruses is, therefore, likely to significantly impact viable vaccine yield. The current crisis is definitely going to have a strong impact on the virus purification products market.
Several recent developments have taken place in the field of viral vector purification. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Viral Vector Purification / Virus Purification Products Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030’ report features an extensive study of various products available for viral vector purification, in addition to the current market landscape and future potential of product developers. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for viral vector purification product developers, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] key geographical regions (North America, Europe, Asia Pacific and rest of the world).
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the viral vector purification product in the short to mid-term, and long term.
Chapter 3 provides a general overview of various types of viral and non-viral vectors. It includes a detailed discussion on the methods of gene transfer, type of viral vectors and applications of viral vectors in various advanced therapies. It provides information on the different stages of the viral vector purification process, type of purification techniques used and the key challenges associated with the purification of viral vectors. Further, it includes a review of the latest trends and innovations in the vector purification market.
Chapter 4 is an overview of the various types of products used for purification techniques based on principles of chromatography, centrifugation and filtration. It highlights product specific information, such as type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration), scale of operation (lab-scale, clinical and commercial), type of viral vector (adenovirus, AAV, lentivirus, retrovirus and others), type of chromatographic technique (affinity chromatography, ion-exchange chromatography, size-exclusion chromatography and hydrophilic interaction chromatography), pack size (wherever specified) and price (wherever specified). In addition, the chapter provides details on certain additional parameters (based on the purification technique, wherever applicable), such as type of matrix, binding capacity, particle size, volume of bed, flow rate, operating pressure, working temperature, process time and pH. The chapter also provides information on the purification product developers, including year of establishment, company size and location of headquarters.
Chapter 5 includes detailed profiles of players offering products for viral vector purification. Each profile features an overview of the company, , information on its product portfolio, recent developments and an informed future outlook.
Chapter 6 highlights potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on multiple parameters, such as type of viral vector, developer strength, operational strength, therapeutic areas, strength of clinical pipeline and strength of preclinical pipeline. The analysis aims to provide the necessary inputs to the product developers, enabling them to make the right decisions to collaborate with industry stakeholders with relatively more initiatives in the domain.
Chapter 7 features a geographical clinical trial analysis of completed, ongoing and planned studies of viral vector-based cell therapies, gene therapies and vaccines (approved / under development). The analysis provides details related to the different types of viral vectors investigated / being investigated across various geographies, based on the number of clinical trials, registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, number of patients enrolled, key players and type of viral vector.
Chapter 8 features an informed estimate of the annual demand for viral vectors, taking into account the viral vector based marketed therapies and clinical studies. For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies, based on various parameters, such as target patient population, dosing frequency and dose strength. The chapter features analyses demand on the basis of type of viral vector, type of therapy, therapeutic are and geographical location.
Chapter 9 is a detailed case study which provides an overview of the tangential flow filtration, highlighting its role, advantages and disadvantages. It features key details of the products used for tangential flow filtration, such as type of product, scale of operation, membrane material, flow rate and filtration area.
Chapter 10 is a detailed case study which provides an overview of the viral vector manufacturers. It features an in-depth analysis of the commercial scale viral vector manufacturers, highlighting details on their year of establishment, company size, types of vectors (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), headquarters and manufacturing facilities.
Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of the virus purification products market till the year 2030. We have segregated the opportunity of the market on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] geographical location (North America, Europe, Asia Pacific and rest of the world).
Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order) Haifeng Chen (Chief Executive Officer, Virovek), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences) and Kai Lipinski (Chief Scientific Officer, Vibalogics).
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix, which provides a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Methods of Gene Transfer
3.3. Viral Vectors for Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
3.6. Applications of Viral Vectors
3.6.1. Cell and Gene Therapy
3.6.1. Vaccinology
3.7. Current Trends in Vector Development / Manufacturing
3.7.1. Vector Engineering
3.7.2. Cargo Engineering
3.8. Vector Manufacturing
3.8.1. Types of Vector Manufacturers
3.8.2. Viral Vector Manufacturing Process
3.8.3. Challenges Related to Vector Manufacturing
3.8.3.1. Vector Purification Process
3.8.3.2. Techniques Used for Vector Purification
3.8.3.2.1. Centrifugation and Ultra-Centrifugation
3.8.3.2.2. Filtration
3.8.3.2.3. Chromatography
3.8.3.3. Challenges Related to Vector Purification
3.9. Future of Vector Purification
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vector Purification Products: Overall Market Landscape
4.2.1. Analysis by Type of Product
4.2.2. Analysis by Type of Purification Technique
4.2.3. Analysis by Scale of Operation
4.2.5. Analysis by Type of Viral Vector
4.2.6. Viral Vector Purification Products for Chromatography
4.2.6.1. Analysis by Type of Chromatographic Technique
4.2.7. Viral Vector Purification Products for Centrifugation
4.2.8. Viral Vector Purification Products for Filtration
4.3. Viral Vector Purification Product Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Agilent Technologies
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. BIA Separations
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. Bio-Rad Laboratories
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. BioVision
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
5.6. Cytiva (formerly GE Lifesciences)
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Merck
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments and Future Outlook
5.8. Sartorius
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.3. Recent Developments and Future Outlook
5.9. Takara Bio
5.9.1. Company Overview
5.9.2. Product Portfolio
5.9.3. Recent Developments and Future Outlook
5.10. Thermo Fisher Scientific
5.10.1. Company Overview
5.10.2. Product Portfolio
5.10.3. Recent Developments and Future Outlook
6. STRATEGIC PARTNER ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. Potential Strategic Partners: Viral Vector-based Therapy Developers
6.3.1. Strategic Partner Analysis: AAV Vector-based Therapy Developers
6.3.1.1. Most Likely Partners
6.3.1.2. Likely Partners
6.3.1.3. Less Likely Partners
6.3.1.4. Least Likely Partners
6.3.2. Strategic Partner Analysis: Adenoviral Vector-based Therapy Developers
6.3.2.1. Most Likely Partners
6.3.2.2. Likely Partners
6.3.2.3. Less Likely Partners
6.3.2.4. Least Likely Partners
6.3.3. Strategic Partner Analysis: Lentiviral Vector-based Therapy Developers
6.3.3.1. Most Likely Partners
6.3.3.2. Likely Partners
6.3.3.3. Less Likely Partners
6.3.3.4. Least Likely Partners
6.3.4. Strategic Partner Analysis: Retroviral Vector-based Therapy Developers
6.3.4.1. Most Likely Partners
6.3.4.2. Likely Partners
6.3.4.3. Less Likely Partners
6.3.4.4. Least Likely Partners
6.3.5. Strategic Partner Analysis: Other Viral Vector-based Therapy Developers
6.3.5.1. Most Likely Partners
6.3.5.2. Likely Partners
6.3.5.3. Less Likely Partners
6.3.5.4. Least Likely Partners
6.4. Potential Strategic Partners: Viral Vector Manufacturers
6.4.1. Strategic Partner Analysis: AAV Vector Manufacturers
6.4.1.1. Most Likely Partners
6.4.1.2. Likely Partners
6.4.1.3. Less Likely Partners
6.4.1.4. Least Likely Partners
6.4.2. Strategic Partner Analysis: Adenoviral Vector Manufacturers
6.4.2.1. Most Likely Partners
6.4.2.2. Likely Partners
6.4.2.3. Less Likely Partners
6.4.2.4. Least Likely Partners
6.4.3. Strategic Partner Analysis: Lentiviral Vector Manufacturers
6.4.3.1. Most Likely Partners
6.4.3.2. Likely Partners
6.4.3.3. Less Likely Partners
6.4.3.4. Least Likely Partners
6.4.4. Strategic Partner Analysis: Retroviral Vector Manufacturers
6.4.4.1. Most Likely Partners
6.4.4.2. Likely Partners
6.4.4.3. Less Likely Partners
6.4.4.4. Least Likely Partners
6.4.5. Strategic Partner Analysis: Other Viral Vector Manufacturers
6.4.5.1. Most Likely Partners
6.4.5.2. Likely Partners
6.4.5.3. Less Likely Partners
6.4.5.4. Least Likely Partners
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Viral Vector based Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Therapy
7.3.5. Analysis by Therapeutic Area
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Analysis by Geographical Location and Trial Status
7.3.8. Most Active Players: Analysis by Number of Registered Trials
7.3.9. Analysis by Patients Enrolled and Trial Phase
7.3.10. Analysis by Patients Enrolled and Type of Therapy
7.3.11. Analysis by Patients Enrolled and Therapeutic Area
7.3.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.4. AAV Vector based Therapies
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Therapy
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Type of Sponsor / Collaborator
7.4.7. Analysis by Geographical Location and Trial Status
7.4.8. Most Active Players: Analysis by Number of Registered Trials
7.4.9. Analysis by Patients Enrolled and Trial Phase
7.4.10. Analysis by Patients Enrolled and Type of Therapy
7.4.11. Analysis by Patients Enrolled and Therapeutic Area
7.4.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.5. Adenoviral Vector based Therapies
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Therapy
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Type of Sponsor / Collaborator
7.5.7. Analysis by Geographical Location and Trial Status
7.5.8. Most Active Players: Analysis by Number of Registered Trials
7.5.9. Analysis by Patients Enrolled and Trial Phase
7.5.10. Analysis by Patients Enrolled and Type of Therapy
7.5.11. Analysis by Patients Enrolled and Therapeutic Area
7.5.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.6. Lentiviral Vector based Therapies
7.6.1. Analysis by Trial Registration Year
7.6.2. Analysis by Trial Phase
7.6.3. Analysis by Trial Status
7.6.4. Analysis by Type of Therapy
7.6.5. Analysis by Therapeutic Area
7.6.6. Analysis by Type of Sponsor / Collaborator
7.6.7. Analysis by Geographical Location and Trial Status
7.6.8. Most Active Players: Analysis by Number of Registered Trials
7.6.9. Analysis by Patients Enrolled and Trial Phase
7.6.10. Analysis by Patients Enrolled and Type of Therapy
7.6.11. Analysis by Patients Enrolled and Therapeutic Area
7.6.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.7. Retroviral Vector based Therapies
7.7.1. Analysis by Trial Registration Year
7.7.2. Analysis by Trial Phase
7.7.3. Analysis by Trial Status
7.7.4. Analysis by Type of Therapy
7.7.5. Analysis by Therapeutic Area
7.7.6. Analysis by Type of Sponsor / Collaborator
7.7.7. Analysis by Geographical Location and Trial Status
7.7.8. Most Active Players: Analysis by Number of Registered Trials
7.7.9. Analysis by Patients Enrolled and Trial Phase
7.7.10. Analysis by Patients Enrolled and Type of Therapy
7.7.11. Analysis by Patients Enrolled and Therapeutic Area
7.7.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.8. Other Viral Vector based Therapies
7.8.1. Analysis by Trial Registration Year
7.8.2. Analysis by Trial Phase
7.8.3. Analysis by Trial Status
7.8.4. Analysis by Type of Therapy
7.8.5. Analysis by Therapeutic Area
7.8.6. Analysis by Type of Sponsor / Collaborator
7.8.7. Analysis by Geographical Location and Trial Status
7.8.8. Most Active Players: Analysis by Number of Registered Trials
7.8.9. Analysis by Patients Enrolled and Trial Phase
7.8.10. Analysis by Patients Enrolled and Type of Therapy
7.8.11. Analysis by Patients Enrolled and Therapeutic Area
7.8.12. Analysis by Patients Enrolled, Trial Status and Geographical Location
8. DEMAND ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Global, Clinical Demand for Viral Vectors
8.3.1. Analysis by Type of Vector
8.3.2. Analysis by Type of Therapy
8.3.3. Analysis by Therapeutic Area
8.3.4. Analysis by Geographical Location
8.4. Global, Commercial Demand for Viral Vectors
8.4.1. Analysis by Type of Vector
8.4.2. Analysis by Type of Therapy
8.4.3. Analysis by Therapeutic Area
8.4.4. Analysis by Geographical Location
9. CASE STUDY: TANGENTIAL FLOW FILTRATION (TFF)
9.1. Chapter Overview
9.2. Role of TFF in Viral Vector Purification
9.2.1. Advantages of TFF
9.2.2. Disadvantages of TFF
9.3. TFF-related Product Suppliers
10. CASE STUDY: VIRAL VECTOR MANUFACTURERS
10.1. Chapter Overview
10.2. Commercial Scale Viral Vector Manufacturers
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Type of Viral Vector
10.2.4. Analysis by Purpose of Production
10.2.5. Analysis by Geographical Location
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Viral Vector Purification Products Market, 2020-2030
11.3.1. Viral Vector Purification Products Market: Distribution by Type of Viral Vector, 2020-2030
11.3.2. Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.3.3. Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.3.4. Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.3.5. Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.3.6. Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.4. Viral Vector Purification Products Market for AAV Vectors, 2020-2030
11.4.1. AAV Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.4.2. AAV Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.4.3. AAV Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.4.4. AAV Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.4.5. AAV Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.5. Viral Vector Purification Products Market for Adenoviral Vectors, 2020-2030
11.5.1. Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.5.2. Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.5.3. Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.5.4. Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.5.5. Adenoviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.6. Viral Vector Purification Products Market for Lentiviral Vectors, 2020-2030
11.6.1. Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.6.2. Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.6.3. Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.6.4. Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.6.5. Lentiviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.7. Viral Vector Purification Products Market for Retroviral Vectors, 2020-2030
11.7.1. Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.7.2. Retroviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.7.3. Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.7.4. Retroviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.7.5. Retroviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
11.8. Viral Vector Purification Products Market for Other Viral Vectors, 2020-2030
11.8.1. Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030
11.8.2. Other Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030
11.8.3. Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030
11.8.4. Other Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030
11.8.5. Other Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030
12. CONCLUDING REMARKS
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Virovek
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Haifeng Chen, Chief Executive Officer
13.3. Vigene Biosciences
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer
13.4. Vibalogics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Kai Lipinski, Chief Scientific Officer
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Gene Transfer: Viral and Non-Viral Methods
Figure 3.2 Vector Manufacturing: Different Types of Manufacturers
Figure 3.3 Vector Manufacturing: Process Steps
Figure 4.1 Viral Vector Purification Products: Distribution by Type of Product
Figure 4.2 Viral Vector Purification Products: Distribution by Type of Purification Technique
Figure 4.3 Viral Vector Purification Products: Distribution by Scale of Operation
Figure 4.4 Viral Vector Purification Products: Distribution by Type of Viral Vector
Figure 4.5 Viral Vector Purification Products: Distribution by Type of Chromatographic Technique
Figure 4.6 Viral Vector Purification Product Developers: Distribution by Year of Establishment
Figure 4.7 Viral Vector Purification Product Developers: Distribution by Company Size
Figure 4.8 Viral Vector Purification Product Developers: Distribution by Geographical Location
Figure 7.1 Viral Vector based Therapies: Distribution by Trial Registration Year
Figure 7.2 Viral Vector-based Therapies: Distribution by Trial Phase
Figure 7.3 Viral Vector-based Therapies: Distribution by Trial Status
Figure 7.4 Viral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.5 Viral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.6 Viral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.7 Viral Vector-based Therapies: Distribution by Geographical Location and Trial Status
Figure 7.8 Viral Vector based Therapies: Most Active Players by Number of Registered Trials
Figure 7.9 Viral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.10 Viral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.11 Viral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.12 Viral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.13 AAV Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.14 AAV Vector-based Therapies: Distribution by Trial Phase
Figure 7.15 AAV Vector-based Therapies: Distribution by Trial Status
Figure 7.16 AAV Vector-based Therapies: Distribution by Type of Therapy
Figure 7.17 AAV Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.18 AAV Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.19 AAV Vector--based Therapies: Distribution by Geographical Location and Trial Status
Figure 7.20 AAV Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.21 AAV Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.22 AAV Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.23 AAV Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.24 AAV Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.25 Adenoviral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.26 Adenoviral Vector-based Therapies: Distribution by Trial Phase
Figure 7.27 Adenoviral Vector-based Therapies: Distribution by Trial Status
Figure 7.28 Adenoviral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.29 Adenoviral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.30 Adenoviral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.31 Adenoviral Vector-based Therapies: Distribution by Geographical Location and Trial Status
Figure 7.32 Adenoviral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.33 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.34 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.35 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.36 Adenoviral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.37 Lentiviral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.38 Lentiviral Vector-based Therapies: Distribution by Trial Phase
Figure 7.39 Lentiviral Vector-based Therapies: Distribution by Trial Status
Figure 7.40 Lentiviral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.41 Lentiviral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.42 Lentiviral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.43 Lentiviral Vector-based Therapies: Distribution by Geographical Location
Figure 7.44 Lentiviral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.45 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.46 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.47 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.48 Lentiviral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.49 Retroviral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.50 Retroviral Vector-based Therapies: Distribution by Trial Phase
Figure 7.51 Retroviral Vector-based Therapies: Distribution by Trial Status
Figure 7.52 Retroviral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.53 Retroviral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.54 Retroviral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.55 Retroviral Vector-based Therapies: Distribution by Geographical Location
Figure 7.56 Retroviral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.57 Retroviral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.58 Retroviral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.59 Retroviral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.60 Retroviral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.61 Other Viral Vector-based Therapies: Distribution by Trial Registration Year
Figure 7.62 Other Viral Vector-based Therapies: Distribution by Trial Phase
Figure 7.63 Other Viral Vector-based Therapies: Distribution by Trial Status
Figure 7.64 Other Viral Vector-based Therapies: Distribution by Type of Therapy
Figure 7.65 Other Viral Vector-based Therapies: Distribution by Therapeutic Area
Figure 7.66 Other Viral Vector-based Therapies: Distribution by Type of Sponsor / Collaborator
Figure 7.67 Other Viral Vector-based Therapies: Distribution by Geographical Location
Figure 7.68 Other Viral Vector-based Therapies: Most Active Players by Number of Registered Trials
Figure 7.69 Other Viral Vector-based Therapies: Distribution by Patients Enrolled and Trial Phase
Figure 7.70 Other Viral Vector-based Therapies: Distribution by Patients Enrolled and Type of Therapy
Figure 7.71 Other Viral Vector-based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.72 Other Viral Vector-based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 8.1. Global Clinical Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Figure 8.2. Clinical Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Figure 8.3. Clinical Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Figure 8.4. Clinical Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Figure 8.5. Clinical Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Figure 8.6. Global Commercial Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Figure 8.7. Commercial Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Figure 8.8. Commercial Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Figure 8.9. Commercial Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Figure 8.10. Commercial Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Figure 10.1 Commercial Scale Viral Vector Manufacturers: Distribution by Year of Establishment
Figure 10.2 Commercial Scale Viral Vector Manufacturers: Distribution by Company Size
Figure 10.3 Commercial Scale Viral Vector Manufacturers: Distribution by Type of Viral Vector
Figure 10.4 Commercial Scale Viral Vector Manufacturers: Distribution by Purpose of Production
Figure 10.5 Commercial Scale Viral Vector Manufacturers: Distribution by Geographical Location
Figure 11.1 Overall Viral Vector Purification Products Market, 2020-2030 (USD Million)
Figure 11.2 Viral Vector Purification Products Market: Distribution by Type of Viral Vector, 2020-2030 (USD Million)
Figure 11.3 Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.4 Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.5 Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.6 Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.7 Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.8 Viral Vector Purification Products Market for AAV Vectors, 2020-2030 (USD Million)
Figure 11.9 AAV Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.10 AAV Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.11 AAV Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.12 AAV Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.13 AAV Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.14 Viral Vector Purification Products Market for Adenoviral Vectors, 2020-2030 (USD Million)
Figure 11.15 Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.16 Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.17 Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.18 Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.19 Adenoviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.20 Viral Vector Purification Products Market for Lentiviral Vectors, 2020-2030 (USD Million)
Figure 11.21 Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.22 Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.23 Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.24 Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.25 Lentiviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.26 Viral Vector Purification Products Market for Retroviral Vectors, 2020-2030 (USD Million)
Figure 11.27 Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.28 Retroviral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.29 Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.30 Retroviral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.31 Retroviral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Figure 11.32 Viral Vector Purification Products Market for Other Viral Vectors, 2020-2030 (USD Million)
Figure 11.33 Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, 2020-2030 (USD Million)
Figure 11.34 Other Viral Vector Purification Products Market: Distribution by Type of Therapy, 2020-2030 (USD Million)
Figure 11.35 Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 11.36 Other Viral Vector Purification Products Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 11.37 Other Viral Vector Purification Products Market: Distribution by Geographical Location, 2020-2030 (USD Million)
Table 3.1 Key Comparison of Different Types of Viral Vectors
Table 4.1 List of Viral Vector Purification Products
Table 4.2 Viral Vector Purification Products for Chromatography: Additional Details
Table 4.3 Viral Vector Purification Products for Centrifugation: Additional Details
Table 4.4 Viral Vector Purification Products for Filtration: Additional Details
Table 4.5 List of Viral Vector Purification Products Developers
Table 5.1 Agilent Technologies: Company Snapshot
Table 5.2 Agilent Technologies: Recent Developments and Future Outlook
Table 5.3 BIA Separations: Company Snapshot
Table 5.4 BIA Separations: Recent Developments and Future Outlook
Table 5.5 Bio-Rad Laboratories: Company Snapshot
Table 5.6 Bio-Rad Laboratories: Recent Developments and Future Outlook
Table 5.7 BioVision: Company Snapshot
Table 5.8 BioVision: Recent Developments and Future Outlook
Table 5.9 Cytiva (formerly GE Lifesciences): Company Snapshot
Table 5.10 Cytiva (formerly GE Lifesciences): Recent Developments and Future Outlook
Table 5.11 Merck: Company Snapshot
Table 5.12 Merck: Recent Developments and Future Outlook
Table 5.13 Sartorius: Company Snapshot
Table 5.14 Sartorius: Recent Developments and Future Outlook
Table 5.15 Takara Bio: Company Snapshot
Table 5.16 Takara Bio: Recent Developments and Future Outlook
Table 5.17 Thermo Fisher Scientific: Company Snapshot
Table 5.18 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 6.2 AAV Vector-based Therapy Developers: Likely Partners
Table 6.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 6.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 6.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 6.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 6.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 6.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 6.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 6.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 6.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 6.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 6.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 6.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 6.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 6.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 6.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 6.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 6.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 6.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 6.21 AAV Vector Manufacturers: Most Likely Partners
Table 6.22 AAV Vector Manufacturers: Likely Partners
Table 6.23 AAV Vector Manufacturers: Less Likely Partners
Table 6.24 AAV Vector Manufacturers: Least Likely Partners
Table 6.25 Adenoviral Vector Manufacturers: Most Likely Partners
Table 6.26 Adenoviral Vector Manufacturers: Likely Partners
Table 6.27 Adenoviral Vector Manufacturers: Less Likely Partners
Table 6.28 Adenoviral Vector Manufacturers: Least Likely Partners
Table 6.29 Lentiviral Vector Manufacturers: Most Likely Partners
Table 6.30 Lentiviral Vector Manufacturers: Likely Partners
Table 6.31 Lentiviral Vector Manufacturers: Less Likely Partners
Table 6.32 Lentiviral Vector Manufacturers: Least Likely Partners
Table 6.33 Retroviral Vector Manufacturers: Most Likely Partners
Table 6.34 Retroviral Vector Manufacturers: Likely Partners
Table 6.35 Retroviral Vector Manufacturers: Less Likely Partners
Table 6.36 Retroviral Vector Manufacturers: Least Likely Partners
Table 6.37 Other Viral Vector Manufacturers: Most Likely Partners
Table 6.38 Other Viral Vector Manufacturers: Likely Partners
Table 6.39 Other Viral Vector Manufacturers: Less Likely Partners
Table 6.40 Other Viral Vector Manufacturers: Least Likely Partners
Table 9.1 List of TFF Products
Table 10.1 List of Commercial Scale Vector Manufacturers
Table 12.1 Concluding Remarks
Table 13.1 Virovek: Company Snapshot
Table 13.2 Vigene Biosciences: Company Snapshot
Table 13.3 Vibalogics: Company Snapshot
Table 14.1 Viral Vector Purification Products: Distribution by Type of Product
Table 14.2 Viral Vector Purification Products: Distribution by Type of Purification Technique
Table 14.3 Viral Vector Purification Products: Distribution by Scale of Operation
Table 14.4 Viral Vector Purification Products: Distribution by Type of Viral Vector
Table 14.5 Viral Vector Purification Products: Distribution by Type of Chromatographic Technique
Table 14.6 Viral Vector Purification Product Developers: Distribution by Year of Establishment
Table 14.7 Viral Vector Purification Product Developers: Distribution by Company Size
Table 14.8 Viral Vector Purification Product Developers: Distribution by Geographical Location
Table 14.9 Viral Vector based Therapies: Distribution by Trial Registration Year
Table 14.10 Viral Vector based Therapies: Distribution by Trial Phase
Table 14.11 Viral Vector based Therapies: Distribution by Trial Status
Table 14.12 Viral Vector based Therapies: Distribution by Type of Therapy
Table 14.13 Viral Vector based Therapies: Distribution by Therapeutic Area
Table 14.14 Viral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.15 Viral Vector based Therapies: Distribution by Geographical Location and Trial Status
Table 14.16 Viral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.17 Viral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.18 Viral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.19 Viral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.20 Viral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.21 AAV Vector based Therapies: Distribution by Trial Registration Year
Table 14.22 AAV Vector based Therapies: Distribution by Trial Phase
Table 14.23 AAV Vector based Therapies: Distribution by Trial Status
Table 14.24 AAV Vector based Therapies: Distribution by Type of Therapy
Table 14.25 AAV Vector based Therapies: Distribution by Therapeutic Area
Table 14.26 AAV Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.27 AAV Vector based Therapies: Distribution by Geographical Location and Trial Status
Table 14.28 AAV Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.29 AAV Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.30 AAV Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.31 AAV Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.32 AAV Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.33 Adenoviral Vector based Therapies: Distribution by Trial Registration Year
Table 14.34 Adenoviral Vector based Therapies: Distribution by Trial Phase
Table 14.35 Adenoviral Vector based Therapies: Distribution by Trial Status
Table 14.36 Adenoviral Vector based Therapies: Distribution by Type of Therapy
Table 14.37 Adenoviral Vector based Therapies: Distribution by Therapeutic Area
Table 14.38 Adenoviral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.39 Adenoviral Vector based Therapies: Distribution by Geographical Location and Trial Status
Table 14.40 Adenoviral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.41 Adenoviral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.42 Adenoviral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.43 Adenoviral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.44 Adenoviral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.45 Lentiviral Vector based Therapies: Distribution by Trial Registration Year
Table 14.46 Lentiviral Vector based Therapies: Distribution by Trial Phase
Table 14.47 Lentiviral Vector based Therapies: Distribution by Trial Status
Table 14.48 Lentiviral Vector based Therapies: Distribution by Type of Therapy
Table 14.49 Lentiviral Vector based Therapies: Distribution by Therapeutic Area
Table 14.50 Lentiviral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.51 Lentiviral Vector based Therapies: Distribution by Geographical Location
Table 14.52 Lentiviral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.53 Lentiviral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.54 Lentiviral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.55 Lentiviral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.56 Lentiviral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.57 Retroviral Vector based Therapies: Distribution by Trial Registration Year
Table 14.58 Retroviral Vector based Therapies: Distribution by Trial Phase
Table 14.59 Retroviral Vector based Therapies: Distribution by Trial Status
Table 14.60 Retroviral Vector based Therapies: Distribution by Type of Therapy
Table 14.61 Retroviral Vector based Therapies: Distribution by Therapeutic Area
Table 14.62 Retroviral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.63 Retroviral Vector based Therapies: Distribution by Geographical Location
Table 14.64 Retroviral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.65 Retroviral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.66 Retroviral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.67 Retroviral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.68 Retroviral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.69 Other Viral Vector based Therapies: Distribution by Trial Registration Year
Table 14.70 Other Viral Vector based Therapies: Distribution by Trial Phase
Table 14.71 Other Viral Vector based Therapies: Distribution by Trial Status
Table 14.72 Other Viral Vector based Therapies: Distribution by Type of Therapy
Table 14.73 Other Viral Vector based Therapies: Distribution by Therapeutic Area
Table 14.74 Other Viral Vector based Therapies: Distribution by Type of Sponsor / Collaborator
Table 14.75 Other Viral Vector based Therapies: Distribution by Geographical Location
Table 14.76 Other Viral Vector based Therapies: Most Active Players by Number of Registered Trials
Table 14.77 Other Viral Vector based Therapies: Distribution by Patients Enrolled and Trial Phase
Table 14.78 Other Viral Vector based Therapies: Distribution by Patients Enrolled and Type of Therapy
Table 14.79 Other Viral Vector based Therapies: Distribution by Patients Enrolled and Therapeutic Area
Table 14.80 Other Viral Vector based Therapies: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 14.81 Global Clinical Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Table 14.82 Clinical Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Table 14.83 Clinical Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Table 14.84 Clinical Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Table 14.85 Clinical Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Table 14.86 Global Commercial Demand for Viral Vectors, 2020-2030 (Thousand Patients)
Table 14.87 Commercial Demand for Viral Vectors: Distribution by Type of Vector (Thousand Patients)
Table 14.88 Commercial Demand for Viral Vectors: Distribution by Type of Therapy (Thousand Patients)
Table 14.89 Commercial Demand for Viral Vectors: Distribution by Therapeutic Area (Thousand Patients)
Table 14.90 Commercial Demand for Viral Vectors: Distribution by Geographical Location (Thousand Patients)
Table 14.91 Commercial Scale Viral Vector Manufacturers: Distribution by Year of Establishment
Table 14.92 Commercial Scale Viral Vector Manufacturers: Distribution by Company Size
Table 14.93 Commercial Scale Viral Vector Manufacturers: Distribution by Type of Viral Vector
Table 14.94 Commercial Scale Viral Vector Manufacturers: Distribution by Purpose of Production
Table 14.95 Commercial Scale Viral Vector Manufacturers: Distribution by Geographical Location
Table 14.96 Overall Viral Vector Purification Products Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.97 Viral Vector Purification Products Market: Distribution by Type of Viral Vector, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.98 Viral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.99 Viral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.100 Viral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.101 Viral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.102 Viral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.103 Viral Vector Purification Products Market for AAV Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.104 AAV Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.105 AAV Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.106 AAV Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.107 AAV Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.108 AAV Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.109 Viral Vector Purification Products Market for Adenoviral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.110 Adenoviral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.111 Adenoviral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.112 Adenoviral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.113 Adenoviral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.114 Adenoviral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.115 Viral Vector Purification Products Market for Lentiviral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.116 Lentiviral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.117 Lentiviral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.118 Lentiviral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.119 Lentiviral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.120 Lentiviral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.121 Viral Vector Purification Products Market for Retroviral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.122 Retroviral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.123 Retroviral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.124 Retroviral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.125 Retroviral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.126 Retroviral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.127 Viral Vector Purification Products Market for Other Viral Vectors, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.128 Other Viral Vector Purification Products Market: Distribution by Type of Purification Technique, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.129 Other Viral Vector Purification Products Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.130 Other Viral Vector Purification Products Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.131 Other Viral Vector Purification Products Market: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 14.132 Other Viral Vector Purification Products Market: Distribution by Geographical Location, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
The following companies and organizations have been mentioned in the report.
Source 1: alliancerm.org/press-release/the-alliance-for-regenerative-medicine-releases-2019-annual-report-and-sector-year-in-review/
Source 2: www.pharmamanufacturing.com/articles/2019/the-rise-of-gene-therapies/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES